{"filing":{"accession_number":"0001104659-26-080058","cik":"0001601485","ticker":"ELTX","company_name":"Elicio Therapeutics, Inc.","form":"8-K","filing_date":"2026-07-02","report_date":null,"primary_document":"tm2619637d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1601485/000110465926080058/tm2619637d1_8k.htm"},"events":[{"id":15665,"run_id":13966,"accession_number":"0001104659-26-080058","anchor_item_number":"1.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Elicio Therapeutics entered into a Securities Purchase Agreement on July 1, 2026, to issue 4,380,313 shares of common stock at $3.43 per share in a registered direct offering, generating approximately $15 million in gross proceeds. The offering is being made pursuant to an effective Form S-3 registration statement, with proceeds intended to fund clinical development and working capital.","company_name":"Elicio Therapeutics, Inc.","ticker":"ELTX","filing_date":"2026-07-02","form":"8-K","submitted_at":null,"items":[{"id":13530,"accession_number":"0001104659-26-080058","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Elicio entered into a Securities Purchase Agreement on July 1, 2026, to issue 4,380,313 shares of common stock at $3.43 per share in a registered direct offering, generating approximately $15 million in gross proceeds. This is a registered direct offering of equity securities to institutional investors—a classic dilutive issuance. The filing explicitly states the offering is being made pursuant to an effective Form S-3 registration statement, and the company intends to use proceeds to fund clinical development and working capital, indicating material capital-raising activity typical of clinical-stage biotech companies.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T10:21:47.778865+00:00","company_name":"","ticker":null,"filing_date":""},{"id":13531,"accession_number":"0001104659-26-080058","item_number":"8.01","item_title":"Other Events","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses a registered direct offering of 4,380,313 shares of common stock for approximately $15 million gross proceeds. This is a dilutive equity issuance by a clinical-stage biotechnology company raising capital, which materially affects existing shareholders through dilution and is a significant financing event for a small-cap biotech firm.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T10:21:47.778865+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":13530,"accession_number":"0001104659-26-080058","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Elicio entered into a Securities Purchase Agreement on July 1, 2026, to issue 4,380,313 shares of common stock at $3.43 per share in a registered direct offering, generating approximately $15 million in gross proceeds. This is a registered direct offering of equity securities to institutional investors—a classic dilutive issuance. The filing explicitly states the offering is being made pursuant to an effective Form S-3 registration statement, and the company intends to use proceeds to fund clinical development and working capital, indicating material capital-raising activity typical of clinical-stage biotech companies.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T10:21:47.778865+00:00","company_name":"Elicio Therapeutics, Inc.","ticker":"ELTX","filing_date":"2026-07-02"},{"id":13531,"accession_number":"0001104659-26-080058","item_number":"8.01","item_title":"Other Events","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses a registered direct offering of 4,380,313 shares of common stock for approximately $15 million gross proceeds. This is a dilutive equity issuance by a clinical-stage biotechnology company raising capital, which materially affects existing shareholders through dilution and is a significant financing event for a small-cap biotech firm.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T10:21:47.778865+00:00","company_name":"Elicio Therapeutics, Inc.","ticker":"ELTX","filing_date":"2026-07-02"}]}